Press Releases

Bridge Laboratories Dedicates Its Preclinical Drug Development Laboratory in Beijing

November 22nd 2005

Bridge Laboratories Inc., Together with WI Harper and Vital Bridge,
Announce the Dedication of Its State-of-the-Art
Preclinical Drug Development Laboratory at
Zhongguancun Life Science Park in Beijing.

San Francisco, Calif., November 22, 2005 - Bridge Laboratories announced today that it will be dedicating its recently completed Bridge Zhongguancun Preclinical Drug Development Laboratory I on Sunday, November 27, 2005. Expected to attend the dedication ceremony are: San Francisco Mayor Gavin Newsom; Deputy Mayor Beijing Municipal Office Hao Lu; Beijing Deputy Mayor Bo-Yuan Fan; US Embassy Senior Commercial Officer Craig Allen; Former Beijing Deputy Mayor Zhao-Guang Hu; Director of Beijing Municipal Industrial Development Bureau Lian-Yuan Cheng; Director of Beijing Municipal Science Technology Office Hai Feng; and Former San Francisco Mayor Frank Jordon.

This 7,800 m2 facility puts Bridge at the forefront of preclinical outsourcing to China and will be the first and only US level GLP and AAALAC designed facility in China. The Zhongguancum facility will house primates, rodents, canines, rabbits. Services will include: FDA compliant GLP toxicology, pharmacology, predictive PK/ADMET, safety pharmacology, formulation and other services. Through its Vital Bridge joint venture, Bridge has expert local partners in China that provide animal supplies from well known US breeder franchises in Asia.

For Bridge, the opening of this facility marks the next phase in outsourcing preclinical drug development to Asia. By controlling its own facility in China, Bridge will have the capacity and expertise to provide FDA compliant preclinical drug development services to pharmaceutical and biotech companies throughout the world. This new facility positions Bridge as the leading preclinical CRO in China targeting US and EU biopharmaceutical companies.

"The San Francisco bay area is the birthplace of biotech and has remained the worldwide leader in life sciences innovation. Escalation of the price of drugs, as evidenced by California's recent ballot initiative, is an increasing hardship and concern," said San Francisco Mayor Gavin Newsom. "By combining the technical resources and innovation of both the San Francisco bay area and Beijing's life sciences community, this state of the art facility represents the next wave of global cooperation and evolution of life sciences development. Bridge and companies like Bridge will allow San Francisco to remain competitive in the life sciences, and cost effectively develop more drugs, for smaller markets, in the new era of personalized molecular medicine. We are pleased to see that a Bay Area company, Bridge Laboratories, is taking the lead in this exciting global evolution of the very best of the east and west."

Founded in 2004, Bridge Laboratories develops preclinical service and drug development capabilities through leverage of the Asian market. To date, Bridge has been subcontracting work through laboratories in China and Taiwan (Beijing, Shanghai, Chengdu, Taipei and elsewhere). Bridge is the first company to successfully use all China preclinical and CMC data for successful filing of IND's with the U.S. FDA and did so twice this year.

About Pharmaron

Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com.